|
Q4 FY2025
As of Dec 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
|
|---|---|---|
| Current assets: | ||
| Cash | ||
| Restricted cash | ||
| Short-term investments | ||
| Notes receivable, net | ||
| Accounts receivable, net | ||
| Advance to suppliers | ||
| Inventories, net | ||
| Other receivables, net | ||
| Prepayments and other current assets, net | ||
| Other receivable-a related party | ||
| Total current assets | ||
| Non-current assets: | ||
| Property, plant and equipment, net | ||
| Land use rights, net | ||
| Intangible assets, net | ||
| Right-of-use assets, net | ||
| Long-term prepayments | ||
| Deferred IPO expenses | ||
| Net deferred tax assets | ||
| Total non-current assets | ||
| Total assets | ||
| Current liabilities: | ||
| Short-term loans | ||
| Current maturities of long-term loans | ||
| Operating lease liability-current | ||
| Accounts payable | ||
| Contract liabilities | ||
| Taxes payable | ||
| Amount due to related parties | ||
| Accrued expenses and other liabilities | ||
| Total current liabilities | ||
| Non-current liabilities: | ||
| Long-term loans | ||
| Operating lease liability-non-current | ||
| Deferred tax liabilities | ||
| Total non-current liabilities | ||
| Total liabilities | ||
| Shareholders’ equity: | ||
| Ordinary shares, value | ||
| Class A ordinary shares | ||
| Class B ordinary shares | ||
| Total ordinary shares, value | ||
| Additional paid-in capital | ||
| Statutory reserves | ||
| Retained earnings (deficit) | ||
| Accumulated other comprehensive income | ||
| Total Zhengye Biotechnology Holding Limited’s shareholders’ equity | ||
| Noncontrolling interests | ||
| Total equity | ||
| Total liabilities and equity |
Loading...